Holocene Advisors
ZNTL icon

Holocene Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Holocene Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-190,251
Closed -$16M – 1061
2021
Q4 		$16M Buy
+190,251
New +$14.7M 0.08% 210

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Holocene Advisors's ZNTL Position: Q1 2022 in Review

Holocene Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2022, closing a stake of 190,251 shares — an estimated $16M sold.

Holocene Advisors first reported a position in ZNTL in Q4 2021 and held it in 1 quarter. The position peaked at $16M in Q4 2021. 128 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

  • Holocene Advisors reported no remaining Zentalis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Holocene Advisors sold 190,251 Zentalis Pharmaceuticals shares in Q1 2022, an estimated $16M.
  • Holocene Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Holocene Advisors's Zentalis Pharmaceuticals position peaked at $16M in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Holocene Advisors's 13F filing for Q1 2022, filed 16 May 2022.